Overview

Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects

Status:
Completed

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is look at the possible side effects of two different doses of CXA-101/tazobactam, a low dose and a high dose, on participant's heart.

Phase:

Phase 1

Details

Lead Sponsor:

Cubist Pharmaceuticals LLC

Treatments:

Ceftolozane
Cephalosporins
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Penicillanic Acid
Tazobactam